Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34914889

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Jan
First author
Yau T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):4-6. doi: 10.1016/S1470-2045(21)00651-3.
    note
    Source null
    related pmid
    34914890
    relationship
    Comment in

Authors and identifiers

  1. name
    Yau T
    type
    Author
  2. name
    Park JW
    type
    Author
  3. name
    Finn RS
    type
    Author
  4. name
    Cheng AL
    type
    Author
  5. name
    Mathurin P
    type
    Author
  6. name
    Edeline J
    type
    Author
  7. name
    Kudo M
    type
    Author
  8. name
    Harding JJ
    type
    Author
  9. name
    Merle P
    type
    Author
  10. name
    Rosmorduc O
    type
    Author
  11. name
    Wyrwicz L
    type
    Author
  12. name
    Schott E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Yau T
    type
    Author
  2. name
    Park JW
    type
    Author
  3. name
    Finn RS
    type
    Author
  4. name
    Cheng AL
    type
    Author
  5. name
    Mathurin P
    type
    Author
  6. name
    Edeline J
    type
    Author
  7. name
    Kudo M
    type
    Author
  8. name
    Harding JJ
    type
    Author
  9. name
    Merle P
    type
    Author
  10. name
    Rosmorduc O
    type
    Author
  11. name
    Wyrwicz L
    type
    Author
  12. name
    Schott E
    type
    Author
bibliography ids
  1. nci-bib-24ebda9f5269289a0159dbb8
book metadata
content sha256
cfdee32f524e3c894deb847e14f70a18be1ec244686eb7dbd5089691e1336bcd
document type
citation
dois
  1. 10.1016/S1470-2045(21)00604-5
electronic publication date
display
2021 Dec 13
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34914889
immutable id
pubmed:34914889@cfdee32f524e3c894deb847e14f70a18be1ec244686eb7dbd5089691e1336bcd
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
77-90
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):4-6. doi: 10.1016/S1470-2045(21)00651-3.
    note
    Source null
    related pmid
    34914890
    relationship
    Comment in
outcomes validated
false
pmid
34914889
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
65bcdcbc85b2c906e4e69a48fc530f506698b32275ee04115ee1267ce6d44695
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jan
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34914889/
title
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

Preserved source evidence · Not medical advice